Ozurdex recommended for uveitis

The intravitreal implant formulation of dexamethasone (Ozurdex) has had its licence extended to include the treatment of non-infectious uveitis in adults.

In a single, multicentre, masked study, 229 patients with non-infectious intermediate or posterior uveitis were randomised to receive a single 700 microgram or 350 microgram dexamethasone implant or sham, via intravitreal injection.

The proportion of eyes with a vitreous haze score of 0 was 47% for the 700 microgram implant and 36% for the 350 microgram implant and 12% for the sham injection (p<0.001 for both comparisons). This statistically significant difference continued until the end of the study (Week 26). The reduction in visual haze was accompanied by a baseline best-corrected visual acuity improvement of ≥15 letters in the respective treatment groups.

There is currently no experience of repeat administration for this indication.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases